Journal article

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection

R Wong, D Cunningham, Y Barbachano, C Saffery, J Valle, T Hickish, S Mudan, G Brown, A Khan, A Wotherspoon, AS Strimpakos, J Thomas, S Compton, YJ Chua, I Chau

Annals of Oncology | OXFORD UNIV PRESS | Published : 2011

University of Melbourne Researchers

Grants

Awarded by National Institute for Health Research


Funding Acknowledgements

National Health Service (to National Institute for Health Research Biomedical Research Centre); Roche (education grant and bevacizumab).RW has received honorarium and served on the advisory board for Roche; DC has served on uncompensated advisory boards for Roche and Sanofi-Aventis and received research funding from Roche and Sanofi-Aventis; TH has received honorarium and served on the advisory board for Roche and Sanofi-Aventis; SM has served on the advisory board for Roche; YJC has received honorarium from Roche and Sanofi-Aventis; and IC has received honoraria from Roche and Sanofi-Aventis, served on the advisory board for Roche, and received research funding from Roche. All remaining authors have declared no conflicts of interest.